Table 3 Time-dependent parameters used in the model*
From: Cost-utility analysis of infliximab and adalimumab for refractory ulcerative colitis
Point estimate (standard error) | ||||
|---|---|---|---|---|
Time | Usual care | 5 mg/kg infliximab | 10 mg/kg infliximab | Adalimumab |
Week 0-8 | ||||
Remission rate | 0.084(0.017) | 0.363(0.031) | 0.297(0.029) | 0.363(0.031) |
% Non-responders among patients with active UC | 74.4(2.9) | 51.9(4.0) | 49.4(3.8) | 51.9(4.0) |
Week 9-30 | ||||
Maintaining remission rate | 0.520(0.099) | 0.524(0.053) | 0.820(0.045) | 0.524(0.053) |
% Non-responders among patients with active UC | 83.0(2.6) | 71.8(3.5) | 71.3(3.6) | 71.8(3.5) |
Week 31-54 | ||||
Maintaining remission rate | 0.799(0.127) | 0.856(0.066) | 0.781(0.073) | 0.856(0.066) |
% Non-responders among patients with active UC | 96.0(1.9) | 83.5(4.2) | 85.0(4.0) | 83.5(4.2) |
Week>54 | ||||
Maintaining remission rate | 0.799(0.127) | 0.856(0.066) | 0.781(0.073) | 0.856(0.066) |
% Non-responders among patients with active UC | 96.0(1.9) | 83.5(4.2) | 85.0(4.0) | 83.5(4.2) |